Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


1234>>>
77 Items
Title  Creator  Group name  Publishing year 
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer Desroys du Roure et al. EquipeELC 2024-01-30
The mechanosensitive TRPV2 calcium channel promotes human melanoma invasiveness and metastatic potential Shoji et al. EquipeELC 2023-02-06
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial Huober et al. EquipeELC 2023-08-10
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study François-Martin et al. EquipeELC 2023-02-13
First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study Bardol et al. EquipeELC 2023-12-22
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer Rabia et al. EquipeELC 2023
Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer David et al. EquipeELC 2023-11-29
Unusual Focal Lung Uptake without CT Abnormality on a Bone Scan: What Might It Mean? Eberlé et al. EquipeELC 2022-04-08
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity Alcaraz et al. EquipeELC 2022-11-08
Secretion of IL1 by Dedifferentiated Melanoma Cells Inhibits JAK1-STAT3-Driven Actomyosin Contractility of Lymph Node Fibroblastic Reticular Cells Rovera et al. EquipeELC 2022-05-03
Real-world evidence of the management and prognosis of young women (?40?years) with de novo metastatic breast cancer Mallet et al. EquipeELC 2022
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects Leenhardt et al. EquipeELC 2022-04-11
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study Dalenc et al. EquipeELC 2022-03
Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study Fabbro et al. EquipeELC 2022-10-27
Emotional processes in partners' quality of life at various stages of breast cancer pathway: a longitudinal study Baudry et al. EquipeELC 2022-11-24
Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study Vasseur et al. EquipeELC 2022-10
Diagnostic Accuracy of Digital Staining ex vivo Confocal Microscopy for Diagnosing and Subtyping Basal Cell Carcinoma in Fresh Pretherapeutic Punch Biopsies: A Monocentric Prospective Study Bergeret et al. EquipeELC 2022-05-05
Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer Boissière-Michot et al. EquipeELC 2022
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes Carausu et al. EquipeELC 2022-12-01
Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress Baudry et al. EquipeELC 2022-01-05
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France] Franchet et al. EquipeELC 2021-08-12
Upfront surgery or definitive radiotherapy for patients with p16-negative oropharyngeal squamous cell carcinoma. A GETTEC multicentric study Culié et al. EquipeELC 2021-02
TNFR1-d2 carrying the p.(Thr79Met) pathogenic variant is a potential novel actor of TNF?/TNFR1 signalling regulation in the pathophysiology of TRAPS Rittore et al. EquipeELC 2021-02-18
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma Berestjuk et al. EquipeELC 2021-12-27
Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study Milliet et al. EquipeELC 2021-01
1234>>>
77 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés